Ramucirumab (Cyramza): A breakthrough treatment for gastric cancer

P and T

Volumn 40, Issue 7, 2015, Pages

  Singh, Amrita D ^a   Parmar, Sapna ^b  

^a ST JOHN'S UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RAMUCIRUMAB;

ANGIOGENESIS; AREA UNDER THE CURVE; BLOOD PRESSURE MONITORING; DIARRHEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; GENETIC TRANSCRIPTION; HEART INFARCTION; HUMAN; HYPERTENSION; HYPONATREMIA; LEUKOPENIA; LOWER ESOPHAGUS SPHINCTER; NEUTROPENIA; NOTE; PHARMACODYNAMICS; PROTEIN EXPRESSION; PROTEINURIA; RISK FACTOR; STOMACH CANCER; WOUND HEALING;

EID: 84937219701     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (18)

1. Abdel-Rahman O. Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspects. Crit Rev Oncol Hematol 2015;93(1):18-27.
2. American Cancer Society. Detailed guide: stomach cancer. March 2015. Available at: http://www.cancer.org/cancer/stomachcancer/detailedguide/index. Accessed May 15, 2015.
3. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2011. [Based on November 2013 SEER data submission, posted to the SEER website April 2014.] Bethesda, Maryland: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2011. Accessed August 6, 2014.
4. Hu B, El Hajj N, Sittler S, et al. Gastric cancer: classification, histology and application of molecular pathology. J Gastrointest Oncol 2012;3(3):251-261.
5. Phan AT. Chapter 17: Gastric and esophageal cancer. In: Kantarjian HM, Wolff RA, Koller CA, eds. The MD Anderson Manual of Medical Oncology, 2nd ed. New York, New York: McGraw-Hill; 2011. Available at: http://accessmedicine.mhmedical.com.jerome.stjohns.edu:81/content.aspx?bookid=379&Sectionid=39902043. Accessed August 6, 2014.
6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Gastric Cancer V.1.2014. ©National Comprehensive Cancer Network, Inc. 2014. All rights reserved. Accessed August 6, 2014. To view the most recent and complete version of the guideline, go online to NCCN. org. National Comprehensive Cancer Network ®, NCCN®, NCCN Guidelines®, and all other NCCN content are trademarks owned by the National Comprehensive Cancer Network, Inc.
7. Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383(9911):31-39.
8. Kuo HY, Yeh KH. Molecular-targeted therapy for chemotherapy-refractory gastric cancer: a case report and literature review. Anticancer Res 2014;34(7):3695-3699.
9. Cyramza (ramucirumab) prescribing information. Indianapolis, Indiana: Eli Lilly and Company; April 2014.
10. Park DJ, Thomas NJ, Yoon C, et al. Vascular endothelial growth factor A inhibition in gastric cancer. Gastric Cancer 2015;18(1):33-42.
11. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010;28(5):780-787.
12. Wilke H, Cutsem EV, Oh SC, et al. RAINBOW: a global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidinecontaining combination therapy. Presentation at the 2014 Gastrointestinal Cancers Symposium, San Francisco, California, January 16-18, 2014. Abstract published in J Clin Oncol 2014;32(suppl 3):LBA7.
13. Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014;384(9944):665-673.
14. Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015;16(5):499-508.
15. Zhu AX, Finn RS, Mulcahy M, et al. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res 2013;19(23):6614-6623.
16. Carvajal RD, Wong MK, Thompson JA, et al. A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma. Eur J Cancer 2014;50(12):2099-2107.
17. Penson RT, Moore KM, Fleming GF, et al. A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecol Oncol 2014;134(3):478-485.
18. Red Book Online. Ann Arbor, Michigan: Truven Health Analytics. Available at: www.micromedexsolutions.com. Accessed June 10, 2015.